{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:06:36Z","timestamp":1789106796493,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["IITP\u20102026\u2010RS\u20102024\u201000438239"],"award-info":[{"award-number":["IITP\u20102026\u2010RS\u20102024\u201000438239"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS\u20102024\u201000509257"],"award-info":[{"award-number":["RS\u20102024\u201000509257"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs) have emerged as potential adjuncts to insulin therapy for type 1 diabetes mellitus (T1DM). However, interpretation of the available evidence is complicated by substantial primary\u2010study overlap, methodological heterogeneity and variable certainty of evidence. Thus, we conducted an overlap\u2010informed umbrella review to evaluate the efficacy and safety of GLP\u20101RAs as adjunctive therapy in T1DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We searched PubMed\/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and OpenAlex from inception to 22 June 2026, and manually screened reference lists to identify systematic reviews with meta\u2010analyses that included randomized controlled trials (RCTs), either alone or alongside nonrandomized studies, evaluating adjunctive GLP\u20101RA therapy in T1DM. Methodological quality was assessed using AMSTAR 2, and primary\u2010study overlap was quantified using a citation matrix and corrected covered area (CCA). Outcome\u2010specific representative meta\u2010analyses were selected, and their primary\u2010study data were independently reanalyzed using random\u2010effects models. Continuous and dichotomous outcomes were summarized as mean differences (MDs) and risk ratios (RRs), respectively, with 95% confidence intervals (CIs). The certainty of evidence was assessed using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen systematic reviews with meta\u2010analyses encompassing 56 unique primary studies (35 RCTs and 21 nonrandomized studies) were included. The calculated CCA was 19.6%, indicating a very high degree of primary\u2010study overlap, largely driven by the ADJUNCT ONE and ADJUNCT TWO trials. Adjunctive GLP\u20101RA therapy reduced HbA1c (MD, \u22120.23% [95% CI, \u22120.30 to \u22120.17]; moderate certainty), body weight (MD, \u22123.93\u2009kg [\u22124.29 to \u22123.56]; moderate certainty) and total daily insulin dose (MD, \u22125.74\u2009IU\/day [\u22127.30 to \u22124.17]; low certainty). No significant improvement was observed in time in range (MD, 1.99% [95% CI, \u22121.17 to 5.15]; very low certainty). No statistically significant increases were observed in severe hypoglycemia (RR, 0.83 [95% CI, 0.36\u20131.91]; low certainty) or diabetic ketoacidosis (RR, 0.67 [95% CI, 0.16\u20132.86]; low certainty). However, GLP\u20101RAs increased the risks of nausea (RR, 2.88 [95% CI, 2.20\u20133.76]; high certainty), vomiting (RR, 3.11 [1.94\u20134.97]; high certainty), and withdrawal due to adverse events (RR, 2.10 [1.42\u20133.12]; high certainty), whereas the risk of diarrhoea was not significantly increased (RR, 1.88 [0.82\u20134.33]; low certainty).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adjunctive GLP\u20101RA therapy was associated with a modest reduction in HbA1c and clinically relevant reductions in body weight and insulin requirements, without a significant improvement in time in range. Gastrointestinal adverse events were increased, whereas the risks of diabetic ketoacidosis and severe hypoglycemia remained uncertain. These findings do not support routine use but suggest a potential role in selected individuals for whom weight reduction and lower insulin requirements are therapeutic priorities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71325","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:21:49Z","timestamp":1789104109000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Glucagon\u2010Like Peptide\u20101 Receptor Agonists as Adjuncts to Insulin Therapy in Type 1 Diabetes Mellitus: An Overlap\u2010Informed Umbrella Review"],"prefix":"10.1111","author":[{"given":"Okjoo","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Surgery Soonchunhyang University Hospital Bucheon, Soonchunhyang University College of Medicine  Bucheon South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejun","family":"Son","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute Kyung Hee University College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Francisco","family":"L\u00f3pez\u2010Gil","sequence":"additional","affiliation":[{"name":"School of Medicine Universidad Esp\u00edritu Santo  Samborond\u00f3n Ecuador"},{"name":"Faculty of Health Sciences Universidad Aut\u00f3noma de Chile  Temuco Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Rahmati","sequence":"additional","affiliation":[{"name":"CEReSS\u2010Health Service Research and Quality of Life Center Aix\u2010Marseille University  Marseille France"},{"name":"Clinical Research Unit, Delegation a la Recherche Clinique et a l'Innovation du GHT Centre Hospitalier Intercommunal de Toulon La Seyne\u2010sur\u2010Mer  Toulon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-7572","authenticated-orcid":false,"given":"Jiseung","family":"Kang","sequence":"additional","affiliation":[{"name":"School of Health and Environmental Science Korea University College of Health Science  Seoul South Korea"},{"name":"Department of Health and Safety Convergence Science Korea University Graduate School  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong\u2010Seon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Incheon Sejong Hospital  Incheon South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-9948","authenticated-orcid":false,"given":"Dong Keon","family":"Yon","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute Kyung Hee University College of Medicine  Seoul South Korea"},{"name":"Department of Pediatrics Kyung Hee University Medical Center, Kyung Hee University College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"12","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2026.0048","article-title":"Type 1 Diabetes: A Review","volume":"335","author":"Jacobsen L. M.","year":"2026","journal-title":"Journal of the American Medical Association"},{"issue":"3","key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/M22-3078","article-title":"Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes","volume":"176","author":"Fang M.","year":"2023","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-024-02145-x","article-title":"Double Diabetes\u2010When Type 1 Diabetes Meets Type 2 Diabetes: Definition, Pathogenesis and Recognition","volume":"23","author":"Bielka W.","year":"2024","journal-title":"Cardiovascular Diabetology"},{"issue":"12","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","article-title":"The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"64","author":"Holt R. I. G.","year":"2021","journal-title":"Diabetologia"},{"issue":"3","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the Effectiveness and Risks of GLP\u20101 Receptor Agonists","volume":"31","author":"Xie Y.","year":"2025","journal-title":"Nature Medicine"},{"issue":"1","key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon\u2010Like Peptide\u20101 Receptor: Mechanisms and Advances in Therapy","volume":"9","author":"Zheng Z.","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070849","article-title":"Reporting Guideline for Overviews of Reviews of Healthcare Interventions: Development of the PRIOR Statement","volume":"378","author":"Gates M.","year":"2022","journal-title":"BMJ"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page M. J.","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/19322968241309896","article-title":"The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon\u2010Like Peptide Receptor Agonists","volume":"19","author":"Seetharaman S.","year":"2025","journal-title":"Journal of Diabetes Science and Technology"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107157","article-title":"The Opportunities and Challenges of the Disease\u2010Modifying Immunotherapy for Type 1 Diabetes: A Systematic Review and Meta\u2010Analysis","volume":"203","author":"Lin C.","year":"2024","journal-title":"Pharmacological Research"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00553","article-title":"Effects of Sodium\u2010Glucose Cotransporter Inhibitor\/Glucagon\u2010Like Peptide\u20101 Receptor Agonist Add\u2010On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta\u2010Analysis","volume":"11","author":"Kim Y. J.","year":"2020","journal-title":"Frontiers in Endocrinology"},{"issue":"3","key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/dom.14291","article-title":"Comparative Efficacy and Safety of Glucose\u2010Lowering Drugs as Adjunctive Therapy for Adults With Type 1 Diabetes: A Systematic Review and Network Meta\u2010Analysis","volume":"23","author":"Avgerinos I.","year":"2021","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"42","key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1055\/s-0034-1387304","article-title":"GLP\u20101 Analogues in Treatment of Type 1 Diabetes Mellitus","volume":"139","author":"Tolle S.","year":"2014","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"7","key":"e_1_2_11_15_1","doi-asserted-by":"crossref","DOI":"10.1111\/obr.70102","article-title":"Gestational Diabetes Mellitus and Adverse Maternal and Neonatal Health Outcomes: An Umbrella Review of Meta\u2010Analyses","volume":"27","author":"Kang J.","year":"2026","journal-title":"Obesity Reviews"},{"issue":"5","key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/jrsm.1658","article-title":"Estimating Pairwise Overlap in Umbrella Reviews: Considerations for Using the Corrected Covered Area (CCA) Index Methodology","volume":"14","author":"Kirvalidze M.","year":"2023","journal-title":"Research Synthesis Methods"},{"issue":"4","key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s42000-025-00704-9","article-title":"Glucagon\u2010Like Peptide\u20101 Receptor Agonists as Add\u2010On Therapy to Insulin for Type 1 Diabetes Mellitus: A Systematic Review and Meta\u2010Analysis","volume":"24","author":"Rebelos E.","year":"2025","journal-title":"Hormones (Athens, Greece)"},{"key":"e_1_2_11_18_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2026.113270","article-title":"Safety of GLP\u20101 Receptor Agonists in Type 1 Diabetes: A Systematic Review and Meta\u2010Analysis","volume":"237","author":"Kateel R.","year":"2026","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"2","key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/dom.70298","article-title":"Efficacy and Safety of Glucagon\u2010Like Peptide 1 Receptor Agonists Across All Health Outcomes in Type 2 Diabetes: An Umbrella Review and Evidence Map of Randomised Controlled Trials","volume":"28","author":"Yeo D.","year":"2026","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"4","key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s13300-017-0282-3","article-title":"Effects of Insulin Plus Glucagon\u2010Like Peptide\u20101 Receptor Agonists (GLP\u20101RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta\u2010Analysis","volume":"8","author":"Wang W.","year":"2017","journal-title":"Diabetes Therapy"},{"key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabres.2017.05.007","article-title":"Efficacy and Safety of Incretin\u2010Based Drugs in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta\u2010Analysis","volume":"129","author":"Wang W.","year":"2017","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"12","key":"e_1_2_11_22_1","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211066306","article-title":"Effects of Incretin\u2010Based Therapies on Beta\u2010Cell Function in Type 1 Diabetes Mellitus: A Systematic Review and Meta\u2010Analysis","volume":"49","author":"Wu Y.","year":"2021","journal-title":"Journal of International Medical Research"},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","DOI":"10.1177\/15209156261420209","article-title":"Efficacy and Safety of Dipeptidyl Peptidase\u20104 Inhibitors, Glucagon\u2010Like Peptide\u20101 Receptor Agonists, and Sodium\u2010Glucose Cotransporter\u20102 Inhibitors as Adjunctive Therapy to Automated Insulin Delivery System in Type 1 Diabetes: A Systematic Review and Meta\u2010Analysis of Randomized Clinical Trials","author":"Zhou Y.","year":"2026","journal-title":"Diabetes Technology & Therapeutics"},{"issue":"1","key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/dom.70188","article-title":"Glucagon\u2010Like Peptide\u20101 Receptor Agonist Treatment Reduces Body Weight and Improves Glycaemic Outcomes in Patients With Concurrent Overweight\/Obesity and Type 1 Diabetes: A Systematic Review and Meta\u2010Analysis","volume":"28","author":"Purcell A. R.","year":"2026","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"1","key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/clinem\/dgad471","article-title":"Glucagon\u2010Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta\u2010Analysis","volume":"109","author":"Park J.","year":"2023","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"12","key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1111\/dom.15979","article-title":"Effects of Glucagon\u2010Like Peptide\u20101 Receptor Agonists on Glycated Haemoglobin and Continuous Glucose Monitoring Metrics as Adjunctive Therapy to Insulin in Adults With Type 1 Diabetes: A Meta\u2010Analysis of Randomized Controlled Trials","volume":"26","author":"Karakasis P.","year":"2024","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"50","key":"e_1_2_11_27_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000046446","article-title":"Impact of Semaglutide Use on Glycemic and Metabolic Profile in Adults With Type 1 Diabetes Having Overweight or Obesity: A Systematic Review and Meta\u2010Analysis","volume":"104","author":"Dutta D.","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"e_1_2_11_28_1","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70111","article-title":"Effect of Glucagon\u2010Like Peptide\u20101 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta\u2010Analysis","volume":"42","author":"Chen Y.","year":"2026","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"e_1_2_11_29_1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1550938","article-title":"The Effects of GLP\u20101 Agonists on HbA1c and Insulin Dose Among Patients With Type 1 Diabetes","volume":"16","author":"Alhowiti A.","year":"2025","journal-title":"Frontiers in Endocrinology"},{"issue":"4","key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1111\/dom.70506","article-title":"Efficacy and Safety of GLP\u20101 Receptor Agonists and SGLT2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Systematic Review and Meta\u2010Analysis","volume":"28","author":"Abdel\u2010Rahman S. M.","year":"2026","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.975880","article-title":"Glucagon\u2010Like Peptide\u20101 Receptor Agonists as Add\u2010On Therapy to Insulin for Type 1 Diabetes Mellitus","volume":"14","author":"Tan X.","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"e_1_2_11_32_1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2026.1758755","article-title":"Glucagon\u2010Like Peptide\u20101 Agonists' Effects on Glycemic Control, Weight Loss, and Beta Cells Function in Type 1 Diabetes","volume":"17","author":"Mirghani H. O.","year":"2026","journal-title":"Frontiers in Endocrinology"},{"issue":"2","key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/dom.14221","article-title":"The Impact of Pharmacological and Lifestyle Interventions on Body Weight in People With Type 1 Diabetes: A Systematic Review and Meta\u2010Analysis","volume":"23","author":"Tandon S.","year":"2021","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"3","key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1530\/EC-18-0546","article-title":"Incretin\u2010Based Therapies for Patients With Type 1 Diabetes: A Meta\u2010Analysis","volume":"8","author":"Liu L.","year":"2019","journal-title":"Endocrine Connections"},{"issue":"4","key":"e_1_2_11_35_1","first-page":"313","article-title":"Liraglutide as Adjunct to Insulin Treatment in Patients With Type 1 Diabetes: A Systematic Review and Meta\u2010Analysis","volume":"16","author":"Dimitrios P.","year":"2020","journal-title":"Current Diabetes Reviews"},{"issue":"4","key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon\u2010Like Peptide\u20101","volume":"27","author":"Drucker D. J.","year":"2018","journal-title":"Cell Metabolism"},{"issue":"4","key":"e_1_2_11_37_1","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/db13-1440","article-title":"Identification and Characterization of GLP\u20101 Receptor\u2010Expressing Cells Using a New Transgenic Mouse Model","volume":"63","author":"Richards P.","year":"2014","journal-title":"Diabetes"},{"issue":"1","key":"e_1_2_11_38_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/db20-0361","article-title":"Glucose Sensing Mediated by Portal Glucagon\u2010Like Peptide 1 Receptor Is Markedly Impaired in Insulin\u2010Resistant Obese Animals","volume":"70","author":"Malbert C. H.","year":"2021","journal-title":"Diabetes"},{"key":"e_1_2_11_39_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074495","article-title":"A Guide and Pragmatic Considerations for Applying GRADE to Network Meta\u2010Analysis","volume":"381","author":"Izcovich A.","year":"2023","journal-title":"BMJ"},{"issue":"21","key":"e_1_2_11_40_1","first-page":"e984","article-title":"Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"143","author":"Powell\u2010Wiley T. M.","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2337\/dc20-2839","article-title":"Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two\u2010Country Nationwide Observational Study","volume":"44","author":"Kristofi R.","year":"2021","journal-title":"Diabetes Care"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71325","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71325","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:21:55Z","timestamp":1789104115000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":40,"alternative-id":["10.1111\/dom.71325"],"URL":"https:\/\/doi.org\/10.1111\/dom.71325","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"2026-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"dom.71325"}}